Empirical models for dosage optimization of four β-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin
Isabelle Delattre(Cliniques Universitaires Saint-Luc), Pierre Wallemacq(Cliniques Universitaires Saint-Luc), Jean Cumps(UCLouvain), Roger K. Verbeeck(UCLouvain), Flora T. Musuamba(Inserm), Thierry Dugernier(Clinique Saint Pierre), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Xavier Wittebole(Cliniques Universitaires Saint-Luc), Herbert Spapen(Universitair Ziekenhuis Brussel), Jean‐Louis Vincent(Université Libre de Bruxelles), Frédérique Jacobs(Université Libre de Bruxelles), Fabio Silvio Taccone(Université Libre de Bruxelles)
Cited by 24
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
|Intensive Care Medicine|1996|11.7k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k